Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 165

1.

A Bispecific Antibody to Link a TRAIL-Based Antitumor Approach to Immunotherapy.

Satta A, Grazia G, Caroli F, Frigerio B, Di Nicola M, Raspagliesi F, Mezzanzanica D, Zaffaroni N, Gianni AM, Anichini A, Figini M.

Front Immunol. 2019 Oct 25;10:2514. doi: 10.3389/fimmu.2019.02514. eCollection 2019.

2.

Guadecitabine Plus Ipilimumab in Unresectable Melanoma: The NIBIT-M4 Clinical Trial.

Di Giacomo AM, Covre A, Finotello F, Rieder D, Danielli R, Sigalotti L, Giannarelli D, Petitprez F, Lacroix L, Valente M, Cutaia O, Fazio C, Amato G, Lazzeri A, Monterisi S, Miracco C, Coral S, Anichini A, Bock C, Nemc A, Oganesian A, Lowder J, Azab M, Fridman WH, Sautès-Fridman C, Trajanoski Z, Maio M.

Clin Cancer Res. 2019 Sep 17. doi: 10.1158/1078-0432.CCR-19-1335. [Epub ahead of print]

PMID:
31530631
3.

Microenvironment and tumor inflammatory features improve prognostic prediction in gastro-entero-pancreatic neuroendocrine neoplasms.

Milione M, Miceli R, Barretta F, Pellegrinelli A, Spaggiari P, Tagliabue G, Centonze G, Paolino C, Mangogna A, Kankava K, Pusceddu S, Giacomelli L, Corti A, Cotsoglou C, Mazzaferro V, Sozzi G, de Braud F, Pruneri G, Anichini A.

J Pathol Clin Res. 2019 Oct;5(4):217-226. doi: 10.1002/cjp2.135. Epub 2019 Jul 9.

4.

Progress in Understanding Complexity and Determinants of Immune-Related Prognostic Subsets in Primary Melanoma.

Anichini A.

Cancer Res. 2019 May 15;79(10):2457-2459. doi: 10.1158/0008-5472.CAN-19-0786.

PMID:
31092407
5.

An actionable axis linking NFATc2 to EZH2 controls the EMT-like program of melanoma cells.

Perotti V, Baldassari P, Molla A, Nicolini G, Bersani I, Grazia G, Benigni F, Maurichi A, Santinami M, Anichini A, Mortarini R.

Oncogene. 2019 May;38(22):4384-4396. doi: 10.1038/s41388-019-0729-2. Epub 2019 Feb 1.

6.

Correction to: NFATc2 is an intrinsic regulator of melanoma dedifferentiation.

Perotti V, Baldassari P, Molla A, Vegetti C, Bersani I, Maurichi A, Santinami M, Anichini A, Mortarini R.

Oncogene. 2019 May;38(19):3763-3764. doi: 10.1038/s41388-019-0679-8.

PMID:
30692631
7.

Semaphorin 5A drives melanoma progression: role of Bcl-2, miR-204 and c-Myb.

D'Aguanno S, Valentini E, Tupone MG, Desideri M, Di Martile M, Spagnuolo M, Buglioni S, Ercolani C, Falcone I, De Dominici M, Milella M, Rizzo MG, Calabretta B, Cota C, Anichini A, Trisciuoglio D, Del Bufalo D.

J Exp Clin Cancer Res. 2018 Nov 19;37(1):278. doi: 10.1186/s13046-018-0933-x.

8.

Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Urothelial Bladder Carcinoma (PURE-01): An Open-Label, Single-Arm, Phase II Study.

Necchi A, Anichini A, Raggi D, Briganti A, Massa S, Lucianò R, Colecchia M, Giannatempo P, Mortarini R, Bianchi M, Farè E, Monopoli F, Colombo R, Gallina A, Salonia A, Messina A, Ali SM, Madison R, Ross JS, Chung JH, Salvioni R, Mariani L, Montorsi F.

J Clin Oncol. 2018 Oct 20:JCO1801148. doi: 10.1200/JCO.18.01148. [Epub ahead of print]

PMID:
30343614
9.

Antibody-Fc/FcR Interaction on Macrophages as a Mechanism for Hyperprogressive Disease in Non-small Cell Lung Cancer Subsequent to PD-1/PD-L1 Blockade.

Lo Russo G, Moro M, Sommariva M, Cancila V, Boeri M, Centonze G, Ferro S, Ganzinelli M, Gasparini P, Huber V, Milione M, Porcu L, Proto C, Pruneri G, Signorelli D, Sangaletti S, Sfondrini L, Storti C, Tassi E, Bardelli A, Marsoni S, Torri V, Tripodo C, Colombo MP, Anichini A, Rivoltini L, Balsari A, Sozzi G, Garassino MC.

Clin Cancer Res. 2019 Feb 1;25(3):989-999. doi: 10.1158/1078-0432.CCR-18-1390. Epub 2018 Sep 11.

PMID:
30206165
10.

Treatment of Advanced Merkel Cell Carcinoma: Current Therapeutic Options and Novel Immunotherapy Approaches.

Femia D, Prinzi N, Anichini A, Mortarini R, Nichetti F, Corti F, Torchio M, Peverelli G, Pagani F, Maurichi A, Mattavelli I, Milione M, Bedini N, Corti A, Di Bartolomeo M, de Braud F, Pusceddu S.

Target Oncol. 2018 Oct;13(5):567-582. doi: 10.1007/s11523-018-0585-y. Review.

PMID:
30073632
11.

Design, selection and optimization of an anti-TRAIL-R2/anti-CD3 bispecific antibody able to educate T cells to recognize and destroy cancer cells.

Satta A, Mezzanzanica D, Caroli F, Frigerio B, Di Nicola M, Kontermann RE, Iacovelli F, Desideri A, Anichini A, Canevari S, Gianni AM, Figini M.

MAbs. 2018 Oct;10(7):1084-1097. doi: 10.1080/19420862.2018.1494105. Epub 2018 Aug 6.

12.

Correction to: Results of nimotuzumab and vinorelbine, radiation and re-irradiation for diffuse pontine glioma in childhood.

Massimino M, Biassoni V, Miceli R, Schiavello E, Warmuth-Metz M, Modena P, Casanova M, Pecori E, Giangaspero F, Antonelli M, Buttarelli FR, Potepan P, Pollo B, Nunziata R, Spreafico F, Podda M, Anichini A, Clerici CA, Sardi I, De Cecco L, Bode U, Bach F, Gandola L.

J Neurooncol. 2018 Jul;138(3):679-680. doi: 10.1007/s11060-018-2893-6.

PMID:
29767306
13.

The non-small cell lung cancer immune landscape: emerging complexity, prognostic relevance and prospective significance in the context of immunotherapy.

Anichini A, Tassi E, Grazia G, Mortarini R.

Cancer Immunol Immunother. 2018 Jun;67(6):1011-1022. doi: 10.1007/s00262-018-2147-7. Epub 2018 Mar 7. Review.

PMID:
29516154
14.

Innovative Therapy, Monoclonal Antibodies and Beyond.

Di Nicola M, Apetoh L, Bellone M, Colombo MP, Dotti G, Ferrone S, Muscolini M, Hiscott J, Anichini A, Pupa SM, Braud F, Del Vecchio M.

Cytokine Growth Factor Rev. 2017 Dec;38:1-9. doi: 10.1016/j.cytogfr.2017.10.002. Epub 2017 Oct 5.

PMID:
29029813
15.

Of Chemoimmunotherapy Sequences and Delayed Disease-modifying Activity in Advanced Urothelial Carcinoma: Vetus Fit Novum.

Necchi A, Anichini A, Sonpavde G.

Eur Urol. 2018 Feb;73(2):153-155. doi: 10.1016/j.eururo.2017.09.012. Epub 2017 Sep 28. No abstract available.

PMID:
28967552
16.

IL-15, TIM-3 and NK cells subsets predict responsiveness to anti-CTLA-4 treatment in melanoma patients.

Tallerico R, Cristiani CM, Staaf E, Garofalo C, Sottile R, Capone M, Pico de Coaña Y, Madonna G, Palella E, Wolodarski M, Carannante V, Mallardo D, Simeone E, Grimaldi AM, Johansson S, Frumento P, Gulletta E, Anichini A, Colucci F, Ciliberto G, Kiessling R, Kärre K, Ascierto PA, Carbone E.

Oncoimmunology. 2016 Dec 7;6(2):e1261242. doi: 10.1080/2162402X.2016.1261242. eCollection 2017.

17.

Cancer immunotherapy: from the lab to clinical applications-Potential impact on cancer centres' organisation.

Cairns L, Aspeslagh S, Anichini A, Kyte JA, Blank C, Ascierto P, Rekers N, Straten PT, Awada A.

Ecancermedicalscience. 2016 Nov 10;10:691. eCollection 2016.

18.

Early Effector T Lymphocytes Coexpress Multiple Inhibitory Receptors in Primary Non-Small Cell Lung Cancer.

Tassi E, Grazia G, Vegetti C, Bersani I, Bertolini G, Molla A, Baldassari P, Andriani F, Roz L, Sozzi G, Pastorino U, Mortarini R, Anichini A.

Cancer Res. 2017 Feb 15;77(4):851-861. doi: 10.1158/0008-5472.CAN-16-1387. Epub 2016 Dec 15.

19.

Brentuximab Vedotin in CD30-Expressing Germ Cell Tumors After Chemotherapy Failure.

Necchi A, Anichini A, Raggi D, Giannatempo P, Magazzù D, Nicolai N, Colecchia M, Paolini B, Coradeschi E, Tassi E, Grazia G, Mortarini R, Calareso G, De Fato R, Togliardi E, Crippa F, Salvioni R, Valagussa P, Gianni AM.

Clin Genitourin Cancer. 2016 Aug;14(4):261-264.e4. doi: 10.1016/j.clgc.2016.03.020. Epub 2016 Mar 24. No abstract available.

PMID:
27105722
20.

Primary cross-resistance to BRAFV600E-, MEK1/2- and PI3K/mTOR-specific inhibitors in BRAF-mutant melanoma cells counteracted by dual pathway blockade.

Penna I, Molla A, Grazia G, Cleris L, Nicolini G, Perrone F, Picciani B, Del Vecchio M, de Braud F, Mortarini R, Anichini A.

Oncotarget. 2016 Jan 26;7(4):3947-65. doi: 10.18632/oncotarget.6600.

21.

HLA class I downregulation is associated with enhanced NK-cell killing of melanoma cells with acquired drug resistance to BRAF inhibitors.

Sottile R, Pangigadde PN, Tan T, Anichini A, Sabbatino F, Trecroci F, Favoino E, Orgiano L, Roberts J, Ferrone S, Kärre K, Colucci F, Carbone E.

Eur J Immunol. 2016 Feb;46(2):409-19. doi: 10.1002/eji.201445289. Epub 2015 Dec 20.

22.

NFATc2 is an intrinsic regulator of melanoma dedifferentiation.

Perotti V, Baldassari P, Molla A, Vegetti C, Bersani I, Maurichi A, Santinami M, Anichini A, Mortarini R.

Oncogene. 2016 Jun 2;35(22):2862-72. doi: 10.1038/onc.2015.355. Epub 2015 Sep 21. Erratum in: Oncogene. 2019 May;38(19):3763-3764.

PMID:
26387540
23.

A melanoma subtype with intrinsic resistance to BRAF inhibition identified by receptor tyrosine kinases gene-driven classification.

Dugo M, Nicolini G, Tragni G, Bersani I, Tomassetti A, Colonna V, Del Vecchio M, De Braud F, Canevari S, Anichini A, Sensi M.

Oncotarget. 2015 Mar 10;6(7):5118-33.

24.

Sema6A and Mical1 control cell growth and survival of BRAFV600E human melanoma cells.

Loria R, Bon G, Perotti V, Gallo E, Bersani I, Baldassari P, Porru M, Leonetti C, Di Carlo S, Visca P, Brizzi MF, Anichini A, Mortarini R, Falcioni R.

Oncotarget. 2015 Feb 20;6(5):2779-93.

25.

Enrichment of CD56(dim)KIR + CD57 + highly cytotoxic NK cells in tumour-infiltrated lymph nodes of melanoma patients.

Ali TH, Pisanti S, Ciaglia E, Mortarini R, Anichini A, Garofalo C, Tallerico R, Santinami M, Gulletta E, Ietto C, Galgani M, Matarese G, Bifulco M, Ferrone S, Colucci F, Moretta A, Kärre K, Carbone E.

Nat Commun. 2014 Dec 4;5:5639. doi: 10.1038/ncomms6639.

26.

Synergistic anti-tumor activity and inhibition of angiogenesis by cotargeting of oncogenic and death receptor pathways in human melanoma.

Grazia G, Vegetti C, Benigni F, Penna I, Perotti V, Tassi E, Bersani I, Nicolini G, Canevari S, Carlo-Stella C, Gianni AM, Mortarini R, Anichini A.

Cell Death Dis. 2014 Oct 2;5:e1434. doi: 10.1038/cddis.2014.410.

27.

Phase II study of perifosine and sorafenib dual-targeted therapy in patients with relapsed or refractory lymphoproliferative diseases.

Guidetti A, Carlo-Stella C, Locatelli SL, Malorni W, Mortarini R, Viviani S, Russo D, Marchianò A, Sorasio R, Dodero A, Farina L, Giordano L, Di Nicola M, Anichini A, Corradini P, Gianni AM.

Clin Cancer Res. 2014 Nov 15;20(22):5641-51. doi: 10.1158/1078-0432.CCR-14-0770. Epub 2014 Sep 19.

28.

Molecular subtyping of metastatic melanoma based on cell ganglioside metabolism profiles.

Tringali C, Silvestri I, Testa F, Baldassari P, Anastasia L, Mortarini R, Anichini A, López-Requena A, Tettamanti G, Venerando B.

BMC Cancer. 2014 Aug 1;14:560. doi: 10.1186/1471-2407-14-560.

29.

Prediction of survival in patients with thin melanoma: results from a multi-institution study.

Maurichi A, Miceli R, Camerini T, Mariani L, Patuzzo R, Ruggeri R, Gallino G, Tolomio E, Tragni G, Valeri B, Anichini A, Mortarini R, Moglia D, Pellacani G, Bassoli S, Longo C, Quaglino P, Pimpinelli N, Borgognoni L, Bergamaschi D, Harwood C, Zoras O, Santinami M.

J Clin Oncol. 2014 Aug 10;32(23):2479-85. doi: 10.1200/JCO.2013.54.2340. Epub 2014 Jul 7.

30.

Towards combinatorial targeted therapy in melanoma: from pre-clinical evidence to clinical application (review).

Grazia G, Penna I, Perotti V, Anichini A, Tassi E.

Int J Oncol. 2014 Sep;45(3):929-49. doi: 10.3892/ijo.2014.2491. Epub 2014 Jun 10. Review.

31.

Results of nimotuzumab and vinorelbine, radiation and re-irradiation for diffuse pontine glioma in childhood.

Massimino M, Biassoni V, Miceli R, Schiavello E, Warmuth-Metz M, Modena P, Casanova M, Pecori E, Giangaspero F, Antonelli M, Buttarelli FR, Potepan P, Pollo B, Nunziata R, Spreafico F, Podda M, Anichini A, Clerici CA, Sardi I, De Cecco L, Bode U, Bach F, Gandola L.

J Neurooncol. 2014 Jun;118(2):305-312. doi: 10.1007/s11060-014-1428-z. Epub 2014 Apr 3. Erratum in: J Neurooncol. 2018 May 16;:.

PMID:
24696052
32.

BIM upregulation and ROS-dependent necroptosis mediate the antitumor effects of the HDACi Givinostat and Sorafenib in Hodgkin lymphoma cell line xenografts.

Locatelli SL, Cleris L, Stirparo GG, Tartari S, Saba E, Pierdominici M, Malorni W, Carbone A, Anichini A, Carlo-Stella C.

Leukemia. 2014 Sep;28(9):1861-71. doi: 10.1038/leu.2014.81. Epub 2014 Feb 24.

PMID:
24561519
33.

EGFR/MEK/ERK/CDK5-dependent integrin-independent FAK phosphorylated on serine 732 contributes to microtubule depolymerization and mitosis in tumor cells.

Rea K, Sensi M, Anichini A, Canevari S, Tomassetti A.

Cell Death Dis. 2013 Oct 3;4:e815. doi: 10.1038/cddis.2013.353.

34.

Role of macrophage targeting in the antitumor activity of trabectedin.

Germano G, Frapolli R, Belgiovine C, Anselmo A, Pesce S, Liguori M, Erba E, Uboldi S, Zucchetti M, Pasqualini F, Nebuloni M, van Rooijen N, Mortarini R, Beltrame L, Marchini S, Fuso Nerini I, Sanfilippo R, Casali PG, Pilotti S, Galmarini CM, Anichini A, Mantovani A, D'Incalci M, Allavena P.

Cancer Cell. 2013 Feb 11;23(2):249-62. doi: 10.1016/j.ccr.2013.01.008.

35.

Perifosine and sorafenib combination induces mitochondrial cell death and antitumor effects in NOD/SCID mice with Hodgkin lymphoma cell line xenografts.

Locatelli SL, Giacomini A, Guidetti A, Cleris L, Mortarini R, Anichini A, Gianni AM, Carlo-Stella C.

Leukemia. 2013 Aug;27(8):1677-87. doi: 10.1038/leu.2013.28. Epub 2013 Jan 30.

PMID:
23360848
36.

Microfluidic devices modulate tumor cell line susceptibility to NK cell recognition.

Perozziello G, La Rocca R, Cojoc G, Liberale C, Malara N, Simone G, Candeloro P, Anichini A, Tirinato L, Gentile F, Coluccio ML, Carbone E, Di Fabrizio E.

Small. 2012 Sep 24;8(18):2886-94. doi: 10.1002/smll.201200160. Epub 2012 Jul 3.

PMID:
22761002
37.

NFATc2 is a potential therapeutic target in human melanoma.

Perotti V, Baldassari P, Bersani I, Molla A, Vegetti C, Tassi E, Dal Col J, Dolcetti R, Anichini A, Mortarini R.

J Invest Dermatol. 2012 Nov;132(11):2652-60. doi: 10.1038/jid.2012.179. Epub 2012 Jun 21.

38.

IGKV3 proteins as candidate "off-the-shelf" vaccines for kappa-light chain-restricted B-cell non-Hodgkin lymphomas.

Martorelli D, Guidoboni M, De Re V, Muraro E, Turrini R, Merlo A, Pasini E, Caggiari L, Romagnoli L, Spina M, Mortarini R, Gasparotto D, Mazzucato M, Carbone A, Rosato A, Anichini A, Dolcetti R.

Clin Cancer Res. 2012 Aug 1;18(15):4080-91. doi: 10.1158/1078-0432.CCR-12-0763. Epub 2012 Jun 15.

39.

AMPK activators inhibit the proliferation of human melanomas bearing the activated MAPK pathway.

Petti C, Vegetti C, Molla A, Bersani I, Cleris L, Mustard KJ, Formelli F, Hardie GD, Sensi M, Anichini A.

Melanoma Res. 2012 Oct;22(5):341-50. doi: 10.1097/CMR.0b013e3283544929.

PMID:
22588166
40.

Phase II study of sorafenib in patients with relapsed or refractory lymphoma.

Guidetti A, Carlo-Stella C, Locatelli SL, Malorni W, Pierdominici M, Barbati C, Mortarini R, Devizzi L, Matteucci P, Marchianò A, Lanocita R, Farina L, Dodero A, Tarella C, Di Nicola M, Corradini P, Anichini A, Gianni AM.

Br J Haematol. 2012 Jul;158(1):108-19. doi: 10.1111/j.1365-2141.2012.09139.x. Epub 2012 May 10.

PMID:
22571717
41.

Role of Apollon in human melanoma resistance to antitumor agents that activate the intrinsic or the extrinsic apoptosis pathways.

Tassi E, Zanon M, Vegetti C, Molla A, Bersani I, Perotti V, Pennati M, Zaffaroni N, Milella M, Ferrone S, Carlo-Stella C, Gianni AM, Mortarini R, Anichini A.

Clin Cancer Res. 2012 Jun 15;18(12):3316-27. doi: 10.1158/1078-0432.CCR-11-2232. Epub 2012 May 2.

42.

The mitogen-activated protein kinase (MAPK) cascade controls phosphatase and tensin homolog (PTEN) expression through multiple mechanisms.

Ciuffreda L, Di Sanza C, Cesta Incani U, Eramo A, Desideri M, Biagioni F, Passeri D, Falcone I, Sette G, Bergamo P, Anichini A, Sabapathy K, McCubrey JA, Ricciardi MR, Tafuri A, Blandino G, Orlandi A, De Maria R, Cognetti F, Del Bufalo D, Milella M.

J Mol Med (Berl). 2012 Jun;90(6):667-79. doi: 10.1007/s00109-011-0844-1. Epub 2012 Jan 4.

PMID:
22215152
43.

T-cell activation and maturation at tumor site associated with objective response to ipilimumab in metastatic melanoma.

Del Vecchio M, Mortarini R, Tragni G, Di Guardo L, Bersani I, Di Tolla G, Agustoni F, Colonna V, Weber JS, Anichini A.

J Clin Oncol. 2011 Nov 10;29(32):e783-8. doi: 10.1200/JCO.2011.36.5957. Epub 2011 Oct 11. No abstract available.

PMID:
21990398
44.

Pharmacological activation of p53 triggers anticancer innate immune response through induction of ULBP2.

Li H, Lakshmikanth T, Garofalo C, Enge M, Spinnler C, Anichini A, Szekely L, Kärre K, Carbone E, Selivanova G.

Cell Cycle. 2011 Oct 1;10(19):3346-58. doi: 10.4161/cc.10.19.17630. Epub 2011 Oct 1.

PMID:
21941086
45.

Allelic and phenotypic heterogeneity in 49 Italian patients with the muscle form of CPT-II deficiency.

Fanin M, Anichini A, Cassandrini D, Fiorillo C, Scapolan S, Minetti C, Cassanello M, Donati MA, Siciliano G, D'Amico A, Lilliu F, Bruno C, Angelini C.

Clin Genet. 2012 Sep;82(3):232-9. doi: 10.1111/j.1399-0004.2011.01786.x. Epub 2011 Oct 12.

PMID:
21913903
46.

Human cutaneous melanomas lacking MITF and melanocyte differentiation antigens express a functional Axl receptor kinase.

Sensi M, Catani M, Castellano G, Nicolini G, Alciato F, Tragni G, De Santis G, Bersani I, Avanzi G, Tomassetti A, Canevari S, Anichini A.

J Invest Dermatol. 2011 Dec;131(12):2448-57. doi: 10.1038/jid.2011.218. Epub 2011 Jul 28.

47.

Bevacizumab plus fotemustine as first-line treatment in metastatic melanoma patients: clinical activity and modulation of angiogenesis and lymphangiogenesis factors.

Del Vecchio M, Mortarini R, Canova S, Di Guardo L, Pimpinelli N, Sertoli MR, Bedognetti D, Queirolo P, Morosini P, Perrone T, Bajetta E, Anichini A.

Clin Cancer Res. 2010 Dec 1;16(23):5862-72. doi: 10.1158/1078-0432.CCR-10-2363. Epub 2010 Oct 28. Erratum in: Clin Cancer Res. 2011 Feb 1;17(3):630.

48.

Tumor-reactive CD8+ early effector T cells identified at tumor site in primary and metastatic melanoma.

Anichini A, Molla A, Vegetti C, Bersani I, Zappasodi R, Arienti F, Ravagnani F, Maurichi A, Patuzzo R, Santinami M, Pircher H, Di Nicola M, Mortarini R.

Cancer Res. 2010 Nov 1;70(21):8378-87. doi: 10.1158/0008-5472.CAN-10-2028. Epub 2010 Sep 21.

49.

Genotype-phenotype correlations in a large series of patients with muscle type CPT II deficiency.

Anichini A, Fanin M, Vianey-Saban C, Cassandrini D, Fiorillo C, Bruno C, Angelini C.

Neurol Res. 2011 Jan;33(1):24-32. doi: 10.1179/016164110X12767786356390. Epub 2010 Aug 31.

PMID:
20810031
50.

Novel SMAC-mimetics synergistically stimulate melanoma cell death in combination with TRAIL and Bortezomib.

Lecis D, Drago C, Manzoni L, Seneci P, Scolastico C, Mastrangelo E, Bolognesi M, Anichini A, Kashkar H, Walczak H, Delia D.

Br J Cancer. 2010 Jun 8;102(12):1707-16. doi: 10.1038/sj.bjc.6605687. Epub 2010 May 11.

Supplemental Content

Loading ...
Support Center